Recurrent disease in patients with stage III melanoma in the era of adjuvant immune and targeted therapy.

e21570Background: Advancements in systemic therapy have reduced recurrence, and the adoption of nodal surveillance in place of dissection has reduced morbidity for patients with Stage III melanoma....